Brought to you by 
ViaCyte gets exclusive license to assets from Janssen Biotech
04 May 2016
Executive Summary
Janssen Biotech Inc. licensed ViaCyte Inc. exclusive rights to the assets of its BetaLogics group, including intellectual property in the area of metabolic diseases (including diabetes).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ViaCyte gets exclusive license to assets from Janssen Biotech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice